SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys post-earnings selloff is the main focus, as traders weigh shortfalls in GMV and subscription-related metrics against earnings and cash-flow strength and continued revenue growth. The sharp drop and rebound have split the community between dip buyers calling it an overreaction and bears citing high valuation and moderating growth.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A record fiscal-quarter earnings beat and raised full-year outlook, supported by strong bookings and AI-chip testing demand, drove AEHRs sharp rally. Traders welcomed the results and AI growth prospects, while others questioned the valuation and whether the rebound can hold.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

MDGL is under pressure despite strong Q3 results and its first profitable quarter, with traders focused on the stocks sharp fade after an initial post-earnings jump. Bulls cite Rezdiffras commercial momentum and room to grow, while skeptics point to slow market penetration, reimbursement hurdles, spending, and the wait for clinical-outcomes data.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong quarterly results and raised outlook were met with a selloff, as traders focused on slower contract bookings and the stocks high valuation as potential signs that growth may be harder to sustain. Bulls view the pullback as an overreaction to robust AI demand and commercial momentum, while bears argue the bookings trend leaves future growth uncertain.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins third-quarter results and a new share repurchase program are driving attention, with traders highlighting stronger profitability and customer growth. The reaction is divided: bulls see improving fundamentals and buybacks as supportive, while skeptics focus on weak same-store sales, stagnant OTC trading, and uncertainty over a U.S. relisting.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transoceans quarterly results and newly released fleet status report are driving discussion, with traders debating the reported GAAP versus adjusted earnings and questioning the sharp share-price decline. Some see longer-term support from contracts and the Valaris merger, while others remain concerned about dilution, debt and weak price action.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiservs quarterly results beat expectations, management reaffirmed its outlook, doubled its cost-savings target and announced plans to resume share repurchases, prompting a sharp rebound after a prolonged selloff. Bulls see a potential turnaround, while skeptics remain focused on execution and margin pressures; short-squeeze talk is speculative.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels CAN-2409 prostate-cancer program, with traders watching upcoming clinical data presentations and the planned BLA submission; bullish posters point to the positive Phase 3 results, while skeptics question the regulatory timeline, financing and CEO credibility. The debate is amplified by a sharp share-price decline that some attribute to broader biotech weakness and thin trading, while others see it as company-specific selling pressure.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

Backblazes stronger-than-expected Q3 results and raised full-year outlook are driving attention, with traders focused on accelerating B2 cloud-storage growth and its potential role in AI infrastructure. The upbeat reaction has been volatile: bulls see evidence the growth story is gaining traction, while skeptics point to slowing retention, declining legacy backup revenue, and post-earnings profit-taking.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Rokus strong Q3 results, with growth in platform and advertising revenue, are drawing attention as shares reach a 52-week high. Traders are weighing the earnings momentum against the pending Fox acquisition, which caps perceived upside and faces added regulatory scrutiny; Roku also withheld its outlook because of the deal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire...

Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment

Equity

Elicio Therapeutics expects to generate net proceeds of about $15 million from the stock offering.

ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (Elicio or the Company) (NASDAQ: ELTX) for violations of the securities laws.The investigation focuses on whether the Company issued...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026...

Technological Innovations to Wage War Against Some of Medicine's Toughest Diseases

The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. $NTHI, $QURE, $ICCM, $CLPT, $ELTX, $AZTR

Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)

Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) PR Newswire NEW YORK, June 16, 2026 Elicio...

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints

Elicio Therapeutics said the randomized trial, called AMPLIFY-7P, of its experimental immunotherapy did not achieve the pre-specified primary endpoint in certain pancreatic cancer patients. 


Elicio Therapeutics (ELTX) to Release Earnings on Tuesday

Elicio Therapeutics (NASDAQ:ELTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-elicio-therapeutics-inc-stock...

Elicio Therapeutics (NASDAQ:ELTX) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH assumed coverage on Elicio Therapeutics in a research report on Wednesday. They set a "buy" rating and a $20.00 price target for the company...

Elicio Therapeutics (NASDAQ:ELTX) Trading 1.6% Higher   - Here's What Happened

Elicio Therapeutics (NASDAQ:ELTX) Trading 1.6% Higher - Should You Buy...

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

Elicio Therapeutics Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>Elicio expects to use net proceeds from the offering to fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC.</li><li>The offering is expected to conclude on or before July 6.</li><li>On June 15, the company reported a mid-stage study of its experimental drug ELI-002 7P that had failed to meet its primary goal.</li></ul><p>Shares of Elicio Therapeutics (ELTX) plunged over 24% premarket on Thursday after the clinical-stage biotech announced a $15 million registered direct offering. The financing comes less than three weeks after the company's lead pancreatic cancer candidate failed to meet the primary endpoint in a mid-stage study.</p><h2 class="st-heading-2"><strong>Elicio Prices $15M Registered Direct Offering&nbsp;</strong></h2><p>Elicio expects to generate net proceeds of about $15 million, before deducting offering expenses and agent fees. The offering is expected to conclude on or before July 6.</p><p>The company said it had entered into a securities purchase agreement with two institutional investors to sell more than 4.3 million shares.&nbsp;</p><h2 class="st-heading-2"><strong>Proceeds Will Fund Lead Pancreatic Cancer Program</strong></h2><p>The company said it expects to use net proceeds, together with its existing cash reserves and marketable securities, to fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC, the company’s pipeline and platform, and general administrative purposes and working capital.</p><p>Elicio Therapeutics, in its first-quarter earnings report on May 11, noted that the company had raised net proceeds of about $8 million during the quarter and an additional $5 million in the second quarter to date, bringing total net proceeds to about $13 million through its at-the-market program.</p><p>As of March 31, the company had cash and cash equivalents of about $14.9 million and expected them to last through the fourth quarter of 2026.</p><h2 class="st-heading-2"><strong>Elicio’s Financing Follows June Clinical Trial Setback</strong></h2><p>On June 15, the biotech company reported results from a mid-stage study of its experimental drug ELI-002 7P. The study did not meet the primary goal of significantly delaying cancer recurrence in patients who were operated to remove pancreatic cancer.&nbsp;</p><p>The company had said it would plan and focus on its late-stage study for patients with lower risks, who had clean surgical margins. Elicio Therapeutics also said it plans to extend the treatment duration.<br><br>“Promising efficacy signals in patients with lower residual disease burden sharpens our path forward,” said Robert Connelly, Chief Executive Officer at Elicio Therapeutics.</p><p>On the same day, the ELTX stock suffered its biggest loss this year, and plunged more than 72%.</p><h2 class="st-heading-2"><strong>What Retail Thinks Of ELTX</strong></h2><p>On Stocktwits, retail sentiment surrounding the stock has remained ‘bearish’ amid ‘low’ message volumes over the past 24 hours.</p><p><a href="https://stocktwits.com/symbol/ELTX">ELTX stock</a> has declined by more than 36% so far this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-yrd-stock-surging-today-july-2-2026/cZme1iHR7SB">Why Is YRD Stock Surging Today?</a></p>

In this photo illustration, the Elicio Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Current Price	$1.55
Prev Close	$1.59
Open	$1.60
Dividend Yield	0.00%
50-Day Moving Average	$2.03
Beta	0.13
Avg. Volume	275,486.47
PE Ratio	-0.75

52-Week High	$16.00
52-Week Low	$1.44
Market Capitalization	$43.07M
EPS (Annual)	-$2.58
Price to Book	4.39
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

ELTX Fundamentals